对于COVID-19后胆血管病的肝移植:一个案例系列
Yuzuru Sambommatsu1, Charles Mouch2, Anand V Kulkarni3
1Department of Surgery, Division of Transplant Surgery, Hume-Lee Transplant Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
Clinical transplantation
|September 27, 2023
概括
肝移植为COVID-19后胆血管病变提供了可行的治疗方法,这是COVID-19后严重的肝脏疾病. 这项研究显示了可接受的患者和移植的存活率,突出了该程序及时评估的重要性.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 移植手术 移植手术
- 传染性疾病 传染性疾病
背景情况:
- 后COVID-19胆管病变是一种新出现的胆固醇性肝病,预后不佳.
- 严重的COVID-19感染可能导致这种情况,有时需要进行肝移植.
- 了解肝移植对这种特定疾病的结果至关重要.
研究的目的:
- 为了研究COVID-19后胆血管病变患者肝移植的结果.
- 评估肝移植作为一种治疗选择的可行性和有效性.
- 为了解患者和移植的生存率提供见解.
主要方法:
- 追溯的多中心病例系列.
- 包括7名在2020年至2022年间接受肝移植的患者.
- 分析数据,包括时间间隔,捐赠者类型,MELD得分和移植后结果.
主要成果:
- 在最初的COVID-19感染期间,86%的患者需要因急性呼吸窘迫综合征而入住ICU.
- 从COVID-19诊断到胆血管病诊断的中位时间为4个月,到移植为12个月.
- 总体患者和移植的生存率为86%,随访时间中位数为11个月,有1人死于呼吸衰竭.
结论:
- 肝移植是COVID-19后胆血管病变的可行的治疗选择.
- 该研究表明,在这个患者群体中,肝移植的结果是可以接受的.
- 早期识别和适当的管理,包括移植评估,对于有利的结果至关重要.
相关概念视频
01:29Chronic Pancreatitis II: Collaborative Care
108
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
108
01:26Diseases of the Liver and Gallbladder
614
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
614